Pembrolizumab in treating lung adenocarcinoma with malignant pericardial effusion

Article Properties
Cite
Kultan, Juraj, and Ondřej Fischer. “Pembrolizumab in Treating Lung Adenocarcinoma With Malignant Pericardial Effusion”. Onkologie, vol. 14, no. Suppl.G, 2021, pp. 179-83, https://doi.org/10.36290/xon.2020.101.
Kultan, J., & Fischer, O. (2021). Pembrolizumab in treating lung adenocarcinoma with malignant pericardial effusion. Onkologie, 14(Suppl.G), 179-183. https://doi.org/10.36290/xon.2020.101
Kultan J, Fischer O. Pembrolizumab in treating lung adenocarcinoma with malignant pericardial effusion. Onkologie. 2021;14(Suppl.G):179-83.
Refrences
Title Journal Journal Categories Citations Publication Date
Srdeční tamponáda Intervenční a akutní kardiologie 2002
Cardiac Complications of Cancer and Anticancer Treatment 2020
Ústav zdravotnických informací a statistiky ČR 2020
Docetaxel Induced Pericardial Effusion 2007
A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811) British Journal of Cancer
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
  • Medicine: Medicine (General)
 45 2009